Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kymera Therapeutics, Inc. (KYMR : NSDQ)

• Company Description    Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States. Number of Employees: 188

• Price / Volume Information    Yesterday's Closing Price: $91.35 Daily Weekly Monthly 20 Day Moving Average: 818,031 shares Shares Outstanding: 81.64 (millions) Market Capitalization: $7,458.03 (millions) Beta: 2.20 52 Week High: $103.00 52 Week Low: $19.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 25.67% 26.77% 12 Week 37.12% 36.95% Year To Date 17.40% 16.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 North Beacon Street 4th Floor - Watertown,MA 02472 USA ph: 857-285-5300 fax: - investors@kymeratx.com http://www.kymeratx.com

• General Corporate Information    Officers Nello Mainolfi - President and Chief Executive Officer Bruce Booth - Chair of the Board of Directors Bruce Jacobs - Chief Financial Officer Felix Baker - Director Jeff Albers - Director Peer Information Kymera Therapeutics, Inc. (CORR.) Kymera Therapeutics, Inc. (RSPI) Kymera Therapeutics, Inc. (CGXP) Kymera Therapeutics, Inc. (BGEN) Kymera Therapeutics, Inc. (GTBP) Kymera Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501575104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/08/26 Share - Related Items Shares Outstanding: 81.64 Most Recent Split Date: (:1) Beta: 2.20 Market Capitalization: $7,458.03 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.89 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.64 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/08/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.16 Price/Cash Flow: - Price / Sales: 190.20 EPS Growth vs. Year Ago Period: -10.23% vs. Previous Quarter: -7.78% Sales Growth vs. Year Ago Period: -61.17% vs. Previous Quarter: 3.87% ROE 12/31/25 - -28.71 09/30/25 - -32.92 06/30/25 - -31.60 ROA 12/31/25 - -25.13 09/30/25 - -28.21 06/30/25 - -27.12 Current Ratio 12/31/25 - 10.47 09/30/25 - 7.38 06/30/25 - 8.32 Quick Ratio 12/31/25 - 10.47 09/30/25 - 7.38 06/30/25 - 8.32 Operating Margin 12/31/25 - -784.21 09/30/25 - -666.00 06/30/25 - -616.03 Net Margin 12/31/25 - -794.04 09/30/25 - -674.81 06/30/25 - -616.03 Pre-Tax Margin 12/31/25 - -794.04 09/30/25 - -674.81 06/30/25 - -616.03 Book Value 12/31/25 - 21.95 09/30/25 - 13.23 06/30/25 - 14.92 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.09 09/30/25 - 0.19 06/30/25 - 0.23

Powered by Zacks Investment Research ©